CD200

Across TCGA pan-cancer cohorts, CD200 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CD200’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CD200 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CD200 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where CD200 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD200 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.904	<.001	11	view →
LUAD	Female	II,III,IV	−1.181	<.001	9	view →
LSCC	Female	All	−0.900	<.001	9	view →
COAD	Female	III,IV	−0.965	<.001	8	view →
HNSC	All	II,III,IV	−0.369	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CD200–CCRCC

Open the CCRCC breakdown →